| Ytd | 3.17% | |
| 1y | 58.84% |
| Open | 1.48 | Prev Close | 1.47 | Low | 1.45 | High | 1.49 | Mkt Cap | 179.94M |
| Vol | 98.10K | Avg Vol | 1.08M | EPS | -1.26 | P/E | -1.17 | Forward P/E | -5.30 |
| Beta | 0.97 | Short Ratio | 8.43 | Inst. Own | 70.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.52 | 200-d Avg | 1.61 | 1yr Est | 5.90 |
CHRS News
Coherus Oncology, Inc. (NASDAQ:CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncol
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQ
Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipe
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQT
Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus
– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou
Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average rating of
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Re
REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), toda
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Hea
Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average recommend
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Co
Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report)'s share price crossed above its two hundred
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During Wednesday's session, 212 companies made new 52-week lows.
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s p
Thursday's session saw 189 companies set new 52-week lows.
On Wednesday, 216 stocks hit new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
On Friday, 431 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Lows On Monday